Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)

总体项目摘要 遏制COVID-19的传播需要跨基础、转化和应用领域的研究 以理工科为重改善2019冠状病毒病大流行结果的血清学检测中心（STOP- COVID）被提议作为一个跨学科实体，以了解暴露风险、传播 免疫反应、疾病严重程度、保护和检测/疫苗接种的障碍，目的是改善 人口健康和临床结果。该中心将利用最先进的血清学和分子检测， 在俄勒冈州立大学开发的一项对第一反应者的纵向研究中，第一反应者是SARS-CoV-2持续高风险的群体 暴露，以及他们的家庭接触。通过拟议的工作，STOP-COVID调查人员将 了解以下关键方面：（i）在无症状和有症状个体中的传播，（ii）免疫， 宿主和疾病结果的病毒决定因素，以及（iii）与免疫保护相关的因素。中心 调查人员还将确定沟通检测结果和COVID-19相关信息的最佳做法 提高对风险、传播和保护的认识，同时减少获得检测的障碍。 阻止新冠肺炎中心将：目标1通过三种共享资源发展研究所基础设施 核心：1.一个行政核心，提供全面指导和领导，协调所有中心活动 以及Project-Core-SeroNet交互; 2.一个测试和生物储存核心，其作用是执行 在我们的纵向研究中，使用高通量ELISA和中和法进行一线血清学和病毒检测 在俄勒冈州立大学开发的检测方法，并由俄勒冈州立大学分担费用;以及3.数据管理和分析核心， 为项目调查人员提供生物统计学、生物信息学、流行病学的集中资源， 心理测量学专业知识目标2：开展三个创新研究项目，以解决： 血清学和病毒检测，以确定COVID-19的流行，传播和保护，在扩展的第一 应答者队列。该项目还将产生疫苗或单克隆抗体的血清学数据，一旦获得， 项目2：COVID-19严重程度的血清学和分子决定因素， 免疫保护。该项目将评估SARS-CoV-2背景下的COVID-19血清学反应 和普通感冒CoV（CCCoV）抗体，使用对一组抗原特异性的新测定。项目2 将采用转录组学来了解宿主遗传学，CCCoV，其他呼吸道病毒和免疫 项目3：应对不断变化的血清学和病毒信息 在COVID-19期间。该项目将结合项目1和2以及SeroNet的结果，以提供最佳做法 在风险沟通中，提供行为指导以减少传播，并加强保护， 疾病目标3：SeroNet参与和分享数据和最佳做法。我们将利用阻止新冠肺炎 与SeroNet共享数据、结果、试剂和最佳实践的基础设施，这将推动新的发现 并将其转化为可行的战略，以便在受COVID-19影响的所有群体中实施。

Overall Project Summary Stemming the spread of COVID-19 will require research that cross-cuts basic, translational, and applied sciences. The Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP- COVID) is proposed as a transdisciplinary entity to understand the interface between exposure risk, transmission, immune responses, disease severity, protection, and barriers to testing/vaccination, with the goal of improving population health and clinical outcomes. The Center will utilize state-of-the-art serological and molecular tests, developed at OSU, in a longitudinal study of first responders, a group at continual high risk of SARS-CoV-2 exposure, as well as their household contacts. Through the proposed work, STOP-COVID investigators will understand critical aspects of: (i) transmission in both asymptomatic and symptomatic individuals, (ii) immune, host, and viral determinants of disease outcome, and (iii) factors associated with immune protection. Center investigators will also identify best practices for communication of test results and information about COVID-19 to improve understanding of risk, transmission, and protection, while reducing access barriers to testing. The Center to STOP-COVID will: Aim 1 Develop Institute Infrastructure through three shared resource cores: 1. An Administrative Core that provides overall direction and leadership, coordinating all Center activities as well as Project–Core–SeroNet interactions; 2. A Testing and Biorepository Core, whose role is to perform first-tier serologic and viral testing during our longitudinal study using high throughput ELISA and neutralization assays developed at OSU, and cost-shared by OSU; and 3. A Data Management and Analysis Core that will provide project investigators with a centralized resource for biostatistics, bioinformatics, epidemiology, and psychometrics expertise. Aim 2: Conduct three innovative research projects to address: Project 1: Parallel serological and viral testing to determine COVID-19 prevalence, transmission, and protection in extended first responder cohorts. This project will also generate serology data for vaccines or mAbs, once available to this presumably high-priority group; Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection. This project will evaluate COVID-19 serological responses in the context of SARS-CoV-2 and common cold CoV (CCCoV) antibodies, using novel assays specific for a panel of antigens. Project 2 also will employ transcriptomics to understand how host genetics, CCCoV, other respiratory viruses, and immune responses contribute to pathogenesis; and Project 3: Responding to changing serological and viral information around COVID-19. This project will incorporate results from Projects 1 & 2 and SeroNet to inform best practices in risk communication, provide behavioral guidance to decrease transmission, and enhance protection from disease. Aim 3: SeroNet Participation and Sharing of Data and Best Practices. We will leverage STOP-COVID infrastructure to share data, results, reagents, and best practices with SeroNet, which will drive new discoveries and their translation into actionable strategies for implementation across all groups affected by COVID-19.